GastroPlus在PK-PD結合模型的應用文章 （2012—2020年10月）

導  讀

凡默谷技術部精取了2012-2020年10月GastroPlus在PK-PD結合模型中的應用文章9篇。

其中編號1-2的文章是2019年8月-2020年10月新增的文章。

希望對您的業務或專業學習有所幫助。內容如下：

1.  三種姜黃素口服制劑在大鼠中的藥代動力學和藥效學

Pharmacokinetics and pharmacodynamics of three oral formulations of curcumin in rats.

Wang L, Cheng D, Guo Y, Wu R, Yin R, Li S, Kuo HC, Hudlikar R, Yang H, Buckley B, Kong AN. J Pharmacokinet Pharmacodyn. (2020) 47:131–144. IF= 2.461

2.  聯用生理藥代動力學PBPK模型與藥物-靶標滯留時間模型，預測托泊司他Topiroxostat在人體內的PK和PD

Prediction of the pharmacokinetics and pharmacodynamics of topiroxostat in humans by integrating the physiologically based pharmacokinetic model with the drug-target residence time model.

Zhiqiang Luo, Guohua Yu, Xing Han, Tingting Yang, Yanhua Ji, Huating Huang, Guopeng Wangc, Yang Liu, Wenyan Sun. Biomedicine & Pharmacotherapy. Volume 121, January 2020. IF=4.545

3.  咖啡因在孕婦體內處置的PBPK/PD模型

Physiologically Based Pharmacokinetic/ Pharmacodynamic Model for Caffeine Disposition in Pregnancy.

Darakjian LI, Kaddoumi A. Mol Pharm. Jan 28, 2019. IF=4.321

4.  采用PBPK/PD模型，通過大鼠和人的PK數據預測Buagafuran（強效抗焦慮劑）的治療劑量

Prediction of a Therapeutic Dose for Buagafuran, a Potent Anxiolytic Agent by Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Starting from Pharmacokinetics in Rats and Human.

Fen Yang, Baolian Wang, Zhihao Liu, Xuejun Xia, Weijun Wang, Dali Yin, Li Sheng, Yan Li. Front Pharmacol. 2017; 8: 683. IF=4.225

5.  開發PBPK/PD模型，用于預測遺傳多態性對受體/轉運體占據的中樞神經系統藥物PK與PD的影響

Development of a Physiologically Based Pharmacokinetic/Pharmacodynamic Model to Predict the Impact of Genetic Polymorphisms on the Pharmacokinetics and Pharmacodynamics Represented by Receptor/Transporter Occupancy of Central Nervous System Drugs.

Alqahtani S, Kaddoumi A. (2016). Clin Pharmacokinet. Feb 25. IF=4.604

6.  開發PBPK/PD模型，以確定導致恩他卡朋生物利用度低的機制

Development of a Physiologically Based Pharmacokinetic/Pharmacodynamic Model to Identify Mechanisms Contributing to Entacapone Low Bioavailability.

Alqahtani S, Kaddoumi A. (2015). Biopharm Drug Dispos. Aug 21. IF=1.663

7.  開發用于預測吲哚美辛在孕婦體內處置的PBPK/PD模型

Development of Physiologically Based Pharmacokinetic/Pharmacodynamic Model for Indomethacin Disposition in Pregnancy.

Alqahtani S, Kaddoumi A. (2015). PLoS One. Oct 2;10(10). IF=2.74

8.   人乳腺癌小鼠異種移植模型中多種凋亡抑制蛋白（IAPs）拮抗劑（SM-406 / AT-406）的PBPK-PD模型

Physiologically based pharmacokinetic and pharmacodynamic modeling of an antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in a mouse xenograft model of human breast cancer.

Zhang T, Li Y, Zou P, Yu JY, McEachern D, Wang S, Sun D. (2013) Biopharm. & Drug Dispos. DOI: 10.1002/bdd.1850. IF=1.663

9.   抗癌藥物蘿卜硫素在大鼠淋巴細胞中II相代謝/抗氧化酶基因反應的PK和PD

Pharmacokinetics and Pharmacodynamics of Phase II Drug Metabolizing/Antioxidant Enzymes Gene Response by Anti-cancer Agent Sulforaphane in Rat Lymphocytes.

Wang H, Khor TO, Yang Q, Huang Y, Wu TY, Saw CL, Lin W, Androulakis IP, Kong AN. (2012) Mol Pharm. Aug. 29. IF=4.321

點擊查看其他文獻

• GastroPlus在FDA等法規部門的應用文章(2016-2020)